Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
NCT06843512
Not Yet Recruiting
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University, State College, Pennsylvania
Conditions: Weight Loss, Food Selection
Register for Updates
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580
Completed
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.
Gender:
ALL
Ages:
All
Trial Updated:
06/20/2025
Locations: Janssen Investigative Site, Titusville, New Jersey
Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Register for Updates
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
NCT07012642
Recruiting
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: River Center, Red Bank, New Jersey +1 locations
Conditions: Lymphedema
Register for Updates
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
NCT04964388
Terminated
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
Gender:
FEMALE
Ages:
55 years and above
Trial Updated:
05/23/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Register for Updates
GLP-1 RA on Liver OMICS in MASLD
NCT06982378
Not Yet Recruiting
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associ... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/13/2025
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: NAFLD, Diabetes, Obesity
Register for Updates
Comparative Effectiveness of Empagliflozin in the US
NCT03363464
Active Not Recruiting
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014. In contrast with several previous cardiovascular outcomes trials, which failed to demonstrate an association with a higher or a lower risk of cardiovascular outcomes associated with members of other recently marketed antidiabetic classes, the EMPA-REG OUTCOME trial has shown that patients at high cardiovascular risk randomized to empagli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Bringham Women Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
NCT06654219
Not Yet Recruiting
The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pulmonary Aspiration
Register for Updates
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
NCT06903923
Not Yet Recruiting
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management. Participants will: * Take Semaglutide as prescribed or continue to work on lifestyle management for weight loss * Take provided calcium and vitamin D supplements * Attend 6 study visits over 24 months with two at the beginning... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/31/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification, Bone Density, Obesity
Register for Updates
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
NCT00992901
Recruiting
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Post Bariatricsurgery, Hypoglycemia
Register for Updates
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
Register for Updates
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT01851694
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Register for Updates
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
NCT06668935
Recruiting
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: East Coast Institute for Research, LLC, Jacksonville, Florida +1 locations
Conditions: Diabetes Mellitus
Register for Updates